Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)’s share price was down 14.9% during trading on Thursday . The stock traded as low as $0.39 and last traded at $0.40. Approximately 9,235,595 shares were traded during trading, an increase of 239% from the average daily volume of 2,724,728 shares. The stock had previously closed at $0.47.
The stock has a market cap of $8.59 million, a P/E ratio of -0.57 and a beta of -0.13.
Titan Pharmaceuticals (NASDAQ:TTNP) last announced its quarterly earnings data on Wednesday, November 14th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. The business had revenue of $1.65 million during the quarter, compared to analyst estimates of $0.10 million. Titan Pharmaceuticals had a negative return on equity of 1,659.34% and a negative net margin of 295.69%. As a group, equities analysts predict that Titan Pharmaceuticals, Inc. will post -0.42 EPS for the current year.
In related news, Chairman Marc Rubin purchased 400,000 shares of the stock in a transaction dated Friday, September 21st. The stock was purchased at an average price of $0.25 per share, with a total value of $100,000.00. Following the transaction, the chairman now directly owns 556,317 shares in the company, valued at $139,079.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sunil Bhonsle purchased 300,000 shares of the stock in a transaction dated Friday, September 21st. The stock was bought at an average cost of $0.25 per share, with a total value of $75,000.00. Following the transaction, the insider now owns 435,578 shares in the company, valued at $108,894.50. The disclosure for this purchase can be found here. Insiders have acquired 900,000 shares of company stock valued at $225,000 in the last three months. Insiders own 19.50% of the company’s stock.
A hedge fund recently bought a new stake in Titan Pharmaceuticals stock. Perkins Capital Management Inc. purchased a new position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 1,200,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $249,000. Perkins Capital Management Inc. owned about 5.66% of Titan Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/11/16/titan-pharmaceuticals-ttnp-trading-down-14-9.html.
About Titan Pharmaceuticals (NASDAQ:TTNP)
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Further Reading: Balanced Fund
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.